AstraZeneca‘s (NYSE:AZN) decision earlier this year to not license Targacept‘s (NASDAQ:TRGT) compound for attention-deficit/hyperactivity disorder was seen by some as a no confidence vote in the molecule. But Don deBethizy, CEO of Winston-Salem, North Carolina-based Targacept, is making a case for TC-5619, which showed positive results for schizophrenia but failed in a separate ADHD study […]
Now that AstraZeneca (NYSE:AZN) has determined it won’t license Targacept‘s compound for schizophrenia, the drug development company is preparing to raise up to $75 million to develop the drug candidate on its own. Winston-Salem, North Carolina-based Targacept (NASDAQ:TRGT) set the dollar target in a preliminary prospectus filed Tuesday with the U.S. Securities and Exchange Commission. […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If the compound Targacept is developing for patients with schizophrenia has a future as a commercialized drug, it will get there without drug partner AstraZeneca. AstraZeneca (NYSE:AZN) is passing up its option to license the drug compound from Winston-Salem, North Carolina drug development company Targacept (NASDAQ:TRGT). The compound, called TC-5619, showed promising results in phase […]
North Carolina pharmaceutical company Pozen (NASDAQ:POZN) and drug partner AstraZeneca (NYSE:AZN) are taking legal action to block a generic competitor to osteoarthritis drug Vimovo. The companies have filed a patent infringement lawsuit in U.S. District Court for the District of New Jersey against India-based generics company Dr. Reddy’s Laboratories (NYSE:RDY). Dr. Reddy’s notified both companies […]
An experimental attention deficit-hyperactivity disorder (ADHD) drug being developed by Targacept in partnership with AstraZeneca (NYSE:AZN) has failed to hit targets set for a mid-stage clinical trial. Winston-Salem, North Carolina-based Targacept, (NASDAQ:TRGT) said results from a phase 2 proof-of-concept trial for the TC-5619 showed that although patients experienced no adverse effects from the compound, the […]
AstraZeneca's $25 million milestone payment to Pozen helped the Chapel Hill, North Carolina-based pharmaceutical company swing to a fourth-quarter profit of $18.4 million.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The CED Biotech/Life Science Conference didn’t have an official theme, but if it did, it could have been "think early." What the more than 1,000 in attendance got was a steady, instructional drumbeat telling them to think about facing important decisions for their companies and their research and development at earlier stages than they’re accustomed.
Targacept's collaboration and licensing agreement with AstraZeneca is starting to show on its financial results as the Winston-Salem, North Carolina drug company started to receive some of the $200 million payment from the 2009 agreement. The compound that AstraZeneca has licensed will be advancing into late-stage clinical trials later this year.